Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Novacyt   /   Waar beleggen jullie nog meer in

Aandeel Novacyt PSE:ALNOV.FR, FR0010397232

Laatste koers (eur) Verschil Volume
0,604   +0,014   (+2,37%) Dagrange 0,591 - 0,625 492.977   Gem. (3M) 358,5K

Waar beleggen jullie nog meer in

Volgen
2.899 Posts
Pagina: «« 1 ... 44 45 46 47 48 ... 145 »» | Laatste | Omlaag ↓
  12. [verwijderd] 24 juni 2020 14:14
    En goed nieuws BIOC:

    Biocept Enters Into Agreement with Reference-based Pricing Network Medical Cost Containment Professionals, LLC to Process Out-of-Network Claims
    PR Newswire PR Newswire•June 24, 2020
    SAN DIEGO, June 24, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces it has entered into a managed care provider agreement with Medical Cost Containment Professionals, LLC (MCCP) to process out-of-network claims for Biocept's Target Selector™ liquid biopsy testing. MCCP is a reference-based pricing insurance network that includes more than 150,000 providers nationwide.

    Biocept Logo (PRNewsFoto/Biocept, Inc.)
    Biocept Logo (PRNewsFoto/Biocept, Inc.)
    More
    "MCCP has a reputation for paying out-of-network claims correctly, in full and on time; and we are delighted to be working with them," said Dede Goehler, Biocept's Senior Director of Managed Care Strategies. "Under this new relationship, out-of-network claims for our Target Selector™ testing will be adjudicated by MCCP at pre-negotiated pricing in a timely manner, helping to accelerate collections while reducing the length of time receivables remain outstanding."

    "This agreement effectively expands our managed care network of covered lives at a time when the healthcare community increasingly recognizes the importance of our liquid biopsy tests in helping physicians to determine the optimal treatment for their patients with cancer," said Michael Nall, Biocept's President and CEO. "MCCP's network includes 47 million covered lives, with some members covered by multiple plans. We are working to enter into additional similar partnerships that help adjudicate out-of-network claims, as well as with managed care plans for in-network coverage for their members."

    About MCCP
    Medical Cost Containment Professionals, LLC was founded by Principal and CEO Daniel Ayala to help lower the cost of healthcare throughout America. MCCP has been successful in driving down the cost of business for its clients. MCCP's unique business model allows for negotiation of 80% of the claims it receives regardless of the amount. More information is available at www.mccpppo.com.

    About Biocept
    Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. Additionally, Biocept is offering nationwide COVID-19 polymerase chain reaction (PCR) testing to support public health efforts during this unprecedented pandemic. For more information, please visit www.biocept.com.

    Forward-Looking Statements Disclaimer Statement
    This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements regarding the adjudication of testing by MCCP at pre-negotiated pricing in a timely manner and the benefits thereof, the ability of MCCP to negotiate 80% of the claims it receives regardless of the amount, the ability of our platform to identify cancer mutations and alterations, and the ability of our technologies to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. You are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.

    Continue reading
  14. [verwijderd] 24 juni 2020 15:25
    quote:

    KC 1965 schreef op 23 juni 2020 19:06:

    Zojuist SINT gekocht aan 1,36, hopelijk herstelt dat snel:

    SINTX Technologies Inc (SINT)

    NASDAQ

    Melding aanmaken
    Voeg toe aan Portfolio
    1,370 -0,650 -32,18%
    19:04:09 - Real-time Cboe. Valuta in USD ( Algemene voorwaarden )
    Type: Aandeel
    Markt: Verenigde Staten
    ISIN: US8293923079
    CUSIP:

    Dit aandeel heeft ook een PR geplaatst:

    SINTX TECHNOLOGIES ANNOUNCES PUBLICATION OF STUDY TO REDUCE THE SPREAD AND TRANSFER OF CORONAVIRUS
    GlobeNewswire GlobeNewswire•June 24, 2020
    Silicon nitride demonstrates anti-viral properties against SARS-CoV-2 and kills virus within minutes of exposure.

    SALT LAKE CITY, UT, June 24, 2020 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (SINT) (“SINTX” or the “Company”), an original equipment manufacturer (OEM) ceramics company focused on silicon nitride and its applications, today announced positive testing results demonstrating the anti-viral properties of its silicon nitride which may be useful in the reduction of the spread of COVID-19. The study results demonstrated that SINTX’s unique grade of silicon nitride inactivates the SARS-CoV-2 virus within a minute after exposure, and has the potential to decrease the risk of viral disease spread on surfaces.

    Studies have shown that coronavirus spreads between humans when an infected person coughs or sneezes. Also, the virus can remain active on a variety of commonly touched surfaces for hours to days. SINTX believes that by incorporating its unique composition of silicon nitride into products such as face masks, and personal protective equipment, it is possible to manufacture surfaces that inactivate viral particles, thereby limiting the spread of the disease. SINTX envisions incorporating its silicon nitride into high-contact surfaces such as medical equipment, screens, countertops, and doorknobs in locations where viral persistence is a concern, such as homes, casinos, and cruise ships.

    “The study builds upon years of research toward understanding the basic biochemistry of silicon nitride,” said Dr. Sonny Bal, President, and CEO of SINTX. “The antiviral attributes of silicon nitride are consistent with the known antibacterial behavior of silicon nitride. The results with coronavirus inactivation are likewise consistent with an earlier study that showed similar inactivation of other viruses, including Influenza A and Enterovirus, both of which cause human disease.”

    “The study and testing results show promise toward developing a new category of face masks for healthcare professionals and general consumers,” said Bruce Lorange, Founder, and CEO, O2TODAY. “Face masks used by healthcare workers today can capture virus particles, but the virus can remain viable in the mask, even as long 7 days after use. Inclusion of silicon nitride technology into the mask may enhance personal safety while reducing the risk of disease spread.”

    “This antiviral discovery opens many new opportunities for SINTX. In composites, coatings, and mixtures, silicon nitride has maintained its antibacterial and osteogenic properties, even at small fractions. We believe that incorporating our material into a variety of commonly-touched surfaces will discourage viral spread, and contribute to global health by reducing the risk of disease,” Dr. Bal added.

    The present study was done independently, with SINTX supplying its silicon nitride for the testing. The complete data and study can be downloaded at bioRxiv. Additional tests are underway at several U.S. research centers to further understand the isolation and optimization of the antiviral properties of silicon nitride; those results will be shared as they become available.

    About SINTX Technologies, Inc.

    SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company manufactures silicon nitride material and components in its FDA registered and ISO 13485 certified facility. For more information on SINTX Technologies or its silicon nitride material platform, please visit www.sintx.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended (PSLRA) that are subject to several risks and uncertainties. Risks and uncertainties that may cause such differences to include, among other things, that SINTX has not developed any PPE products which incorporate the use of silicon nitride, incorporation of silicon nitride into PPE may not be safe or effective; the uncertainties inherent in research and development, including the cost and time required to advance our products to regulatory submission; market acceptance of our products once cleared and commercialized; our ability to raise additional funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations, and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 26, 2020, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.

    Continue reading

    Laat maar knallen vandaag, gisteren ingestapt aan 1,36

    1,420 -0,590 -29,35%
    23/06 - Gesloten. Valuta in USD ( Algemene voorwaarden )
    Voorbeurs 1,620 +0,200 +14,08% 15:23:22 - Real-time Data
    Type: Aandeel
    Markt: Verenigde Staten
    ISIN: US8293923079
    CUSIP: 829392307
    Volume: 19.896.889 Bied/laat: 1,600 / 1,630 Dagbereik: 1,310 - 1,580
    SINTX Technologies 1,420 -0,590 -29,35%
    Algemeen Grafiek Financiën Technisch Forum
  17. CedricPalmans 24 juni 2020 15:39
    quote:

    KC 1965 schreef op 24 juni 2020 14:10:

    En ik denk met goed nieuws dat dit makkelijk 6-7,- doet.
    met alle respect, maar ik vind dit slaat toch werkelijk nergens op? Waarom zou dat op basis van die info manifest gaan stijgen? Naar 6 betekent 20% omhoog. Omdat ze beginnen testen zijn, wat ze vorige week al hadden aangekondigd?
    Van mij mag het zeker, want ik zit er in, en aan een hogere prijs dan de huidige koers.
    Koersstijgingen verwacht ik pas als er een akkoord is met andere luchthavens, of als er resultaten zijn van hoe het operationeel draait.
  18. CedricPalmans 24 juni 2020 15:40
    quote:

    Gaizka1985 schreef op 24 juni 2020 09:37:

    [...]

    En daar is het nieuws! Ben benieuwd waar de koers naartoe gaat vandaag!
    Ze hadden vorige week al aangegeven dat ze eind deze week gingen beginnnen testen. Weinig wereldschokkends. 't is wachten op andere akkoorden, of goeie resultaten qua operationele werking.
2.899 Posts
Pagina: «« 1 ... 44 45 46 47 48 ... 145 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee